Early and effective detection of addictive and hallucinogen potential in the next generation of psychoactive drugs to speed up the implementation of control measures by the EU.
At the end of 2019, the EMCDDA had identified more than 700 new psychoactive substances (NPS). Among them, there are the new psychostimulants and hallucinogens, which are used as drugs of abuse, but their short/long-term adverse effects are unknown. These NPS are designed to mimic traditional drugs...
By the end of 2019, the EMCDDA monitored around 790 NPS and every year more than 50 NPS are being detected for the first time by the EU-Early Warning System. They emerged due to their availability, price and psychoactive potency. Many of them are designed to mimic existing scheduled drugs and used as an alternative to MDMA, amphetamines, cocaine and LSD. However, the knowledge about...
Getting an accurate diagnosis can be one of the most impactful experiences that you can have.